N-cyclopropylpiperidine-4-carboxamide | 937683-79-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: N-cyclopropylpiperidine-4-carboxamide
• CAS: 937683-79-9
• 化学式: C₉H₁₆N₂O
• 分子量: 168.239
• InChiKey: WJXILHPPCMZNEF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  41.1
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• Novel Compounds 002
  申请人：Beha Sara

  公开号：US20090062251A1

  公开（公告）日：2009-03-05

  Compounds of Formulae I, or pharmaceutically acceptable salts thereof: wherein R 1 , R 2 and Y are as defined in the specification as well as salts and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.

  式I的化合物，或其药用可接受的盐： 其中R1、R2和Y如规范中定义的那样，以及包括这些化合物的盐和药物组合物已经准备好。它们在治疗中很有用，特别是在疼痛管理中。
• [EN] N- CYCLOPROPYL - N- PIPERIDINYLBENZAMIDES AS GPR119 MODULATORS<br/>[FR] N-CYCLOPROPYL-N-PIPÉRIDINYLBENZAMIDES EN TANT QUE MODULATEURS DE GPR119
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2012123449A1

  公开（公告）日：2012-09-20

  The present invention relates to compounds of general formula I, wherein the groups R1, LP, LQ, Ar, mand n are as defined in the application, which have valuable pharmacological properties, and in particular bind to the GPR119 receptor and modulate its activity.

  本发明涉及一般式I的化合物，其中基团R1、LP、LQ、Ar、m和n如申请中所定义，具有有价值的药理特性，特别是结合GPR119受体并调节其活性。
• [EN] 2, 5-DIAMINO-SUBSTITUTED PYRIDO [4, 3-D] PYRIMIDINES AS AUTOTAXIN INHIBITORS AGAINST CANCER<br/>[FR] PYRIDO[4,3-D]PYRIMIDINES 2,5-DIAMINO-SUBSTITUÉES EN TANT QU'INHIBITEURS D'AUTOTAXINE CONTRE LE CANCER
  申请人：MERCK PATENT GMBH

  公开号：WO2010063352A1

  公开（公告）日：2010-06-10

  The present invention relates to pyridopyrimidine derivatives according to formula (I), as autotaxin inhibitors and the use of such compounds for the treatment and/or prophylaxis of physiological and/or pathophysiological conditions, which are caused, mediated and/or propagated by increased lysophosphatic acid levels and/or the activation of autotaxin, in particular of different cancers.

  本发明涉及按照式(I)的吡啶吡嘧啶衍生物，作为自体毒素抑制剂，并且利用这类化合物用于治疗和/或预防由增加的溶磷脂酸水平和/或自体毒素的激活引起、介导和/或传播的生理和/或病理条件，特别是不同癌症。
• 1-[M-CARBOXAMIDO(HETERO)ARYL-METHYL]-PIPERIDINE-4-CARBOXAMIDE DERIVATIVES
  申请人：FRETZ Heinz

  公开号：US20130345199A1

  公开（公告）日：2013-12-26

  The present invention relates to 1-[m-Carboxamido(hetero)aryl-methyl]-piperidine-4-carboxamide derivatives of formula (I) wherein X, Ar 1 , R 1 , R 2 , R 3 , R 4 , R 5 and p are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as CXCR7 receptor modulators.

  本发明涉及公式（I）中的1-[m-羧酰胺（杂）芳基甲基]-哌啶-4-羧酰胺衍生物，其中X、Ar1、R1、R2、R3、R4、R5和p如描述中所述，以及其制备方法，其药学上可接受的盐，以及其作为药物的用途，包括含有一个或多个公式（I）化合物的药物组合物，特别是其作为CXCR7受体调节剂的用途。
• Cannabinoid Receptor Ligands
  申请人：Beha Sara

  公开号：US20110160180A1

  公开（公告）日：2011-06-30

  Compounds of Formulae (I), or pharmaceutically acceptable salts thereof: wherein R 1 , R 2 and Y are as defined in the specification as well as salts and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.

  化学式（I）的化合物，或其药学上可接受的盐：其中R1，R2和Y的定义如规范中所述，以及包括这些化合物的盐和药物组合物已经制备。它们在治疗中有用，特别是在疼痛管理中。